The authors provided an historical view on BRCA1/2 testing performed in nearly 2000 breast/ovarian cancer patients extending from a first-tier BRCA1/2 population-based assay to next-generation sequencing (NGS) in a subset of patients. This evidence concerns the gene BRCA1 and ovarian carcinoma.